Evidence-based effective and safe interventions in ASD are needed to ease some of the behavioral challenges seen in this condition
GLP-1 RAs are particularly effective for promoting weight loss, controlling glycemic levels (notably A1c), and reducing the risk of strokes
Despite their popularity, GLP-1 agonists may contribute to the risk of kidney stone formation in some patients, particularly during the initial phases of treatment, but their long-term metabolic benefits may reduce stone risk over time
HR 1.19, 95% CI 0.91.58), but not for the other DPP-4 inhibitors as in the TECOS study for sitagliptin (HR 1.00, 95% CI 0.831.20) or the CARMELINA study for linagliptin (HR 0.90, 95% CI 0.741.08) (57, 62, 64, 65, 68)